High levels of pigment epithelium-derived factor in the retina of a rat model of type 2 diabetes.
Spontaneously diabetic Torii (SDT) rats are a new animal model of diabetes. To investigate the mechanisms controlling diabetic retinopathy, we examined the retinal changes in SDT rats and determined the molecular balance between pigment epithelium-derived factor (PEDF), an angiogenic inhibitor, and vascular endothelial growth factor (VEGF), a major angiogenic stimulator. The retinopathy in SDT rats was characterized by a low incidence of neovascular formation and absence of non-perfused areas, and high levels of both PEDF and VEGF. Proliferative neovascular membranes, that are similar to that in human eyes with proliferative diabetic retinopathy, were found in the eyes of some of the SDT rats at >50-weeks-of-age, Immunoreactivity for VEGF was detected in the retina of SDT rats and the level of VEGF increased with the duration of diabetes. More importantly, immunoreactivity for PEDF was also increased in the retina of diabetic SDT rats. Western blot analysis showed that the level of VEGF in the retina was increased by 2.4 fold at 20-week-old, and by 6.8 fold at >40-week-old compared to that of 10-weeks old SDT rats. The levels of PEDF in the retina at 20-week- and at >40-week-old were significantly higher than that of 10-weeks old SDT rats (20-week-old; 13.5-fold increase, > 40-week-old; 10.3-fold increase). Earlier studies showed that the level of PEDF was decreased and VEGF was increased in proliferative diabetic retinopathy in human eyes. The high levels of PEDF in the retina of SDT rats may contribute to the low incidence of neovascular formation and absence of non-perfused areas that do not match the typical diabetic retinopathy in humans.
Matsuoka
Masato
M
Department of Ophthalmology, Kansai Medical University, Fumizono-cho 10-15, Moriguchi, Osaka 570-8507, Japan.
Ogata
Nahoko
N
Minamino
Keizo
K
Higuchi
Akiko
A
Matsumura
Miyo
M
D000818:Animals; D015153:Blotting, Western / Q000379:methods; D003924:Diabetes Mellitus, Type 2 / Q000378:metabolism*; D003930:Diabetic Retinopathy / Q000378:metabolism*; D005136:Eye Proteins / Q000032:analysis*; D005451:Fluorescein Angiography; D017127:Glycation End Products, Advanced / Q000032:analysis; D023421:Models, Animal; D009389:Neovascularization, Pathologic; D009414:Nerve Growth Factors / Q000032:analysis*; D051381:Rats; D011922:Rats, Mutant Strains; D012160:Retina / Q000737:chemistry*; D015843:Serpins / Q000032:analysis*; D013997:Time Factors; D042461:Vascular Endothelial Growth Factor A / Q000032:analysis; D000099174:Pigment Epithelium-Derived Factor
D005136:Eye Proteins; D017127:Glycation End Products, Advanced; D009414:Nerve Growth Factors; D015843:Serpins; D042461:Vascular Endothelial Growth Factor A; D000099174:Pigment Epithelium-Derived Factor